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Abstract
Background: Intensive care unit (ICU) outcome prediction models, such as Acute Physiology And Chronic Health
Evaluation (APACHE), were designed in general critical care populations and their use in obstetric populations is
contentious. The aim of the CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of Risk) study
was to develop and internally validate a multivariable prognostic model calibrated specifically for pregnant or
recently delivered women admitted for critical care.
Methods: A retrospective observational cohort was created for this study from 13 tertiary facilities across five highincome and six low- or middle-income countries. Women admitted to an ICU for more than 24 h during pregnancy
or less than 6 weeks post-partum from 2000 to 2012 were included in the cohort. A composite primary outcome
was defined as maternal death or need for organ support for more than 7 days or acute life-saving intervention.
Model development involved selection of candidate predictor variables based on prior evidence of effect,
availability across study sites, and use of LASSO (Least Absolute Shrinkage and Selection Operator) model building
after multiple imputation using chained equations to address missing data for variable selection. The final model
was estimated using multivariable logistic regression. Internal validation was completed using bootstrapping to
correct for optimism in model performance measures of discrimination and calibration.
(Continued on next page)
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Results: Overall, 127 out of 769 (16.5%) women experienced an adverse outcome. Predictors included in the final
CIPHER model were maternal age, surgery in the preceding 24 h, systolic blood pressure, Glasgow Coma Scale
score, serum sodium, serum potassium, activated partial thromboplastin time, arterial blood gas (ABG) pH, serum
creatinine, and serum bilirubin. After internal validation, the model maintained excellent discrimination (area under
the curve of the receiver operating characteristic (AUROC) 0.82, 95% confidence interval (CI) 0.81 to 0.84) and good
calibration (slope of 0.92, 95% CI 0.91 to 0.92 and intercept of −0.11, 95% CI −0.13 to −0.08).
Conclusions: The CIPHER model has the potential to be a pragmatic risk prediction tool. CIPHER can identify
critically ill pregnant women at highest risk for adverse outcomes, inform counseling of patients about risk, and
facilitate bench-marking of outcomes between centers by adjusting for baseline risk.
Keywords: Risk prediction model, High-risk pregnancy, Maternal mortality, Maternal morbidity, Critical care

Background
Most women who die during or soon after pregnancy in
a health facility do so in an intensive care unit (ICU), if
one is available [1–3]. Maternal ICU admissions result
from both obstetric and non-obstetric complications in
pregnancy; about two thirds of admissions are due to
obstetric causes, such as hemorrhage, pre-eclampsia,
and sepsis, and one third are due to maternal medical or
surgical complications [1–3].
ICU clinical prediction models—including Acute Physiology And Chronic Health Evaluation II (APACHE II),
APACHE III, Multiple Organ Dysfunction Score (MODS),
Simplified Acute Physiology Score 3 (SAPS 3), and
Sepsis-related Organ Failure Assessment (SOFA)—were
developed in general ICU populations to assess the likelihood of an adverse health outcome (such as death or severe morbidity) and guide counseling and clinical decision
making [4–8]. However, most ICU outcome prediction
models were designed in general critical care populations
in high-income countries (HICs) and their use in obstetric
populations and in low- and middle-income countries
(LMICs) is contentious. These general ICU prediction
rules tend to overestimate the risk of maternal death by
up to 20-fold [1]. The two exceptions to this are the SOFA
score for sepsis risk and the Maternal Severity Index rule
[9, 10]. None of the obstetric-focused ICU risk models has
been developed to predict maternal death or prolonged
organ support, an outcome reflective of severe maternal
morbidity and of greater relevance in maternity populations among whom death is unusual, even in the ICU.
Maternal Early Warning scores are being adopted in
obstetric care in many settings across the globe. These
scores have resulted in mixed results when validated
[11] and are relevant only for care prior to ICU admission. Given the unique physiology during pregnancy and
post-partum, new pregnancy-specific clinical prediction
rules, specific to the ICU setting, are required [12, 13].
Our objective was to develop and internally validate the
globally relevant CIPHER (Collaborative Integrated
Pregnancy High-dependency Estimate of Risk) model to

predict either death or severe morbidity for pregnant
and post-partum women admitted for critical care.

Methods
Study setting

Thirteen collaborating sites with ICUs from 11 countries
contributed data to the CIPHER cohort. These sites were
identified through a literature review of published obstetric ICU cohorts. After initial contact to establish
whether the investigators were interested in collaborating, they were sent a survey to ensure suitability of the
facility for participation in the CIPHER cohort. This survey evaluated human resources, interventions, and infrastructure available at each ICU site to ensure that sites
were similar with regard to type of care provided. The
HICs were in Canada, the US, Ireland, the Netherlands,
and Australia. The LMIC sites were in Brazil, Argentina,
Jordan, Turkey, Pakistan, and China. (For details, please
see Additional file 1: Table S1.)
Inclusion and exclusion criteria

Women were included if they were admitted to a critical
care unit for more than 24 h and were known to be either pregnant (diagnosed before or during their ICU
stay) or no more than 42 days post-partum, irrespective
of pregnancy duration, from 1 January 2000 to 31 December 2012. Women admitted for less than 24 h who
were neither pregnant nor recently pregnant were excluded, as were women with 10 or more missing candidate predictor variables or those who were missing
primary outcome information or who met the definition
of the primary outcome prior to admission.
Data collection

We carried out a retrospective chart review of both paper
and electronic medical records by using standardized data
collection forms and protocols for all sites. Data were entered into a customized, secure online RedCAP® database.
All data were reviewed for quality and consistency. When
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questions arose regarding data reliability, these data were
confirmed by re-review of the primary health record.
Primary outcome

The composite primary outcome was defined as any one
of (i) maternal death during pregnancy or within 42 days
of delivery or (ii) organ support for more than 7 days or
(iii) life-saving intervention or a combination of these.
Organ support and life-saving interventions included in
this composite were defined by organ system and are
used as a surrogate for severe maternal morbidity. Specifically, organ support outcomes include any one or
more of (1) respiratory (continuous positive airway pressure (CPAP), bilevel positive airway pressure (BiPAP), or
invasive ventilation); (2) cardiac (positive inotrope or
vasopressor use); (3) continuous renal replacement therapy for acute renal failure; (4) hepatic (liver transplantation and other management of hepatic failure (for
example, ventilatory and circulatory support), management of elevated intracranial pressure and renal failure,
and medical therapies for hepatitis B virus (for example,
lamivudine)), and anticoagulation for Budd–Chiari syndrome); (5) hematologic (transfusion of at least 5 units
of blood products); (6) neurological (Glasgow Coma
Scale score of less than 10); or (7) uterine (uncontrollable hemorrhage or infection leading to hysterectomy).
These definitions were arrived at through study working
group consensus and are based on definitions of organ
support used in the APACHE studies [5] and the World
Health Organization (WHO) near-miss approach [10].
Sample size

This sample size estimate is based on a rule of thumb
for developing risk prediction models with unbiased estimates of regression coefficients [14]. The formula—[N
= (n × 10) / I]—was used to calculate the sample size
where N = the required sample size, n = the number of
variables to be tested, and I = the incidence of the combined adverse outcome [14]. We assumed, on the basis
of published reports, I = 12% for either maternal mortality or prolonged organ support for obstetric women admitted for critical care [15]. We estimated that to
develop a reliable model with minimal overfitting with n
= 10 candidate predictor variables at an assumed event
rate of 12%, a cohort of N = 833 women was required.
Model development
Dealing with missing data

Multiple imputation using chained eqs [16, 17] was
undertaken to estimate missing data over 10 iterations
to generate 10 complete datasets for model development. Two analysts replicated this process. We assumed
that data were missing at random [17]. Women with and
without missing data were compared to identify all
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clinical, laboratory, and demographic variables that differed between the groups. These variables were included
in the imputation models along with all selected candidate predictor variables and the primary outcome [18].
Selection of candidate predictor variables

Initially, we performed a structured literature review of
existing critical care outcome prediction models and their
evidence for use in pregnancy to identify candidate predictor variables [1]. This review has been published elsewhere [1]. Variables considered for the CIPHER model
included patient demographic details, prior health status,
indication for ICU admission, and clinical and laboratory
measurements taken in the first 24 h following ICU admission. The literature review identified 43 possible variables to include in the modelling process. This list was
refined and reduced to 19 after exclusion of variables that
were not routinely available at all sites (defined as having
more than 30% missing values in the dataset) and through
iterative dialogue with the participating critical care,
maternal-fetal-medicine, and epidemiology experts in the
CIPHER team to identify concerns about generalizability
of measurements and clinical policy relevant to each variable across study settings.
As a final step, Pearson’s correlation coefficient (for
continuous predictors) or chi-squared test (for categorical variables) was used to estimate any correlation between candidate predictors within each imputed dataset.
Consultation within the study working group was used
when collinearity was suspected to select which variable
to retain on the basis of perceived clinical value, reliability of measurement, and availability. The 14 most clinically relevant, available, and non-correlated variables were
then included in the final variable selection step (Fig. 1).
The LASSO (Least Absolute Shrinkage and Selection
Operator) method was used to reduce the number of
candidate predictors further and select final variables to
include in the CIPHER model [19]. The LASSO selects
variables by penalizing models that have more and larger
coefficients. This requires a choice for the degree to
which to penalize these terms. For this analysis, the penalty term in each imputed dataset was chosen by 10-fold
cross-validation. This process resulted in a variety of
possible penalty “sizes”, and the one in each dataset
yielding the smallest area under the curve of the receiver
operating characteristic (AUROC) was chosen as the
penalty to use. Both squared and cubic transformations
were evaluated at this stage of variable selection for any
candidate predictor variable that was assumed to have a
non-linear relationship with the outcome due to known
increases in clinical risk at both high and low levels.
These variables were identified prior to LASSO model
development as maternal age, blood pressure, serum sodium, and white blood cell count.
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Fig. 1 The process of selection of predictor variables for inclusion in the CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate
of Risk) model. Abbreviations: ABG arterial blood gas, ALT alanine aminotransferase, AST aspartate aminotransferase, BMI body mass index, FiO2
fraction of inspired oxygen, ICU intensive care unit, INR international normalized ratio, LASSO Least Absolute Shrinkage and Selection Operator,
LDH lactate dehydrogenase, MAP mean arterial pressure, SaO2 oxygen saturation.

LASSO models were built using the glmnet package in
R [20]. This variable selection technique was repeated
within each imputed dataset, resulting in 10 models. A
priori, we set thresholds for inclusion in the final
CIPHER model as any variable which retained a
non-zero coefficient in the LASSO model in seven or
more imputations. Variables that maintained a non-zero
coefficient in fewer than seven of the LASSO models
would not be retained for final parameter estimation.
Estimating parameter effects

Multivariable logistic regression was used to estimate
variable effects of selected predictors in each of the 10
imputed datasets. A final pooled estimate of effect was
then generated using Rubin’s rules implemented in
STATA through the mi estimate command [21].
Assessing the model’s performance

The discrimination ability of the final model was evaluated
on the basis of AUROC [22]. Discrimination in this context refers to the ability of the model to distinguish between women with and without outcomes. An AUROC of
more than 0.7 indicates good model discrimination.
Model calibration was assessed by plotting deciles of
the predicted probability of an adverse maternal outcome against the observed rate in each decile and fitting
a smooth line using locally weighted scatterplot smoothing (lowess) using the “rms” and “calibrationcurves”

packages in R [23, 24]. This smooth line is used to determine the calibration slope and intercept [25]. These calibration measures are used to describe the accuracy of
the predicted probability compared with the observed
outcome and are considered measures of model
goodness-of-fit. Ideally, the slope would be close to one
and intercept zero. Discrimination and calibration measures were estimated for each of the imputed datasets
and then pooled using Rubin’s rules. Graphs presented
are drawn using the pooled linear predictor value for
each woman in the dataset.
A risk stratification table was used to evaluate model
classification accuracy and stratification capacity. Both
classification accuracy, defined as the ability of the model
to separate cases with an outcome into higher-risk groups
and cases without an outcome into lower-risk groups, and
stratification capacity, defined as the ability of the model
to separate the population into distinct risk groups, give
additional information on model calibration. A useful
model will separate the population into distinct risk
groups so that the majority of outcome cases result in a
high predicted probability and the remaining cases have a
visibly lower predicted probability, leaving few in the
middle.
Categories within the stratification table were defined
to be balanced around the population prevalence. By
balancing around the population prevalence, we defined
risk groups that have the potential to be meaningfully
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different than the prevalence itself, which represents the
total population risk. Specifically, the lowest and highest
groups were set at predictive probability about three
times greater and less than the prevalence. We calculated the sensitivity, specificity, positive predictive value,
negative predictive value, and likelihood ratios (LRs) for
each risk group. A positive test was defined using the
upper limit of the predicted probability range for each
risk group, except for calculation of the LRs, which
followed the method of Deeks and Altman [26]. These
measures of diagnostic accuracy are used in this study to
describe potential accuracy of the model if it were implemented as a decision rule using the defined risk groups.
The following categories for interpretation of the LRs
were used: strongly informative (LR <0.1 or >10), moderately informative (LR 0.1–0.2 or 5–10), and
non-informative (LR 0.2–5). Uniformity of the model fit
was tested by assessing model performance in various
subsets of study data, including HIC versus LMIC, antenatal versus post-partum admission, and in cases with
obstetric versus other indication for admission.
Model internal validation and optimism correction

Internal validation of the model was assessed in each
of the 10 imputed datasets using Efron’s enhanced
bootstrap method [27]. Details of this approach have
been described previously [28, 29]. Model optimism
was calculated for discrimination (AUROC) as the
average difference between model performance in the
bootstrap sample and the original imputed dataset
after 200 iterations of the bootstrap procedure. This
resulted in 10 estimates of average optimism, which
were pooled using Rubin’s rules to generate a final
optimism result.
In addition, internal validation of the calibration slope
and intercept was completed during the bootstrapping
procedure using the same method as above. For these
measures of model fit, we calculated the average slope
and intercept for each bootstrap model applied to its
original imputed dataset over 200 iterations. This resulted in 10 average slopes and intercepts that were then
pooled using Rubin’s rules to generate final internally
validated measures of model calibration.
All analyses were initially performed in R using the
“mice”, “rms”, “calibrationcurves”, and “glmnet” packages. Pooling of parameter estimates and model performance estimates were repeated by a second analyst to
confirm results using STATA version 13.0.

Results
At the 13 study sites, retrospective chart review was
completed for 876 eligible women who met inclusion
criteria. We excluded 107 women; 93 of these were excluded because they were missing at least 10 out of 19
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candidate predictor variables included in the imputation
step and 14 because they were missing outcome data. A
final cohort of 769 women was identified for analysis.
Characteristics of the study population are presented in
Table 1, comparing women with and without the primary
adverse outcome of death or morbidity, as previously defined. Women with the primary adverse outcome were
younger and more often accessed care through private facilities, were admitted for non-obstetric reasons, were admitted to the ICU earlier in gestation and for longer, and
had a greater number of early pregnancy losses and stillbirths. The primary outcome was observed in 127 (16.5%)
women. Of these, 59 (7.7%) were maternal deaths and 68
(8.8%) required one or more component of organ support
alone. The most common organ support outcome was the
need for respiratory support (Table 2).
Imputation

A comparison of women with and without missing data
shows that women with missing data were less severely
ill and had shorter duration of ICU stay (Additional
file 1: Table S3). Imputation models specified for this
study included all variables that differed between women
with or without one or more missing selected predictor
variable to best account for these differences. Univariate
odds ratios estimated for all candidate predictor variables in both the imputed data (Table 3) and complete
case cohorts (Additional file 1: Table S2) were similar,
and an expected increase in precision was seen in the estimates generated using the imputed data.
Model development

The final variables selected for inclusion in the CIPHER
model were maternal age, surgical status in the preceding
24 h, systolic blood pressure, Glasgow Coma Scale score,
serum sodium, serum potassium, activated partial
thromboplastin time (aPTT), serum creatinine, and serum
bilirubin, and arterial blood gas (ABG) pH (Table 4). The
odds of experiencing an adverse outcome increase as
serum creatinine, total bilirubin, serum sodium, and aPTT
increase; decrease as maternal age and systolic blood pressure decrease; and decrease if ABG pH and Glasgow
Coma Scale score increase or if there was surgery in the
24 h preceding ICU admission (Table 3).
Model performance

The apparent AUROC for the CIPHER model was 0.84
(0.83 to 0.85) (Fig. 2). This model was well calibrated in
the development data, as would be expected, with a calibration slope of 1.0 and intercept of −0.001 (Fig. 3).
Stratification capacity and classification accuracy of the
model as presented in Table 5 were both good; the majority of women identified in the two lowest risk groups
(54.1% women, n = 416) had low rates of adverse
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Table 1 Characteristics of the study population
Patient characteristics

Women with no outcome
(n = 642), median (IQR) or n (%)

Women with outcome
(n = 127), median (IQR) or n (%)

Age, years

31 (26–36)

27 (25–32)

Married

346 (53.9)

90 (70.9)

Single

62 (9.7)

1 (0.8)

Missing

234 (36.4)

36 (28.3)

26.4 (24.0–30.0)

26.2 (23.2–29.1)

Public

383 (59.7)

54 (42.5)

Private

208 (32.4)

73 (57.5)

Missing

Marital status

2

BMI, kg/m

Prenatal care type

51 (7.9)

0 (0.0)

Gravidity

3 (2–4)

4 (2–5)

Parity

1 (1–2)

2 (1–3)

Obstetric*

465 (72.4)

77 (60.6)

Non-obstetric**

263 (41.0)

95 (74.8)

Missing

3 (0.4)

0 (0.0%)

Antepartum

162 (25.2)

46 (36.2)

Intrapartum

6 (0.9)

1 (0.8)

Post-partum

459 (71.5)

77 (60.6)

Missing

Details of ICU admission
Reason for admission‡

Timing of admission

15 (2.3)

3 (2.4)

Gestational age in weeks at ICU admission (for women admitted antepartum)

34.4 (28.7–38.0)

30.9 (22.4–35.8)

External ICU transfer, yes

184 (28.7)

21 (16.5)

Length of ICU stay, hours

59.4 (37.0–92.1)

209.9 (110.7–309.4)

Yes

59 (9.2)

27 (21.3)

Missing

29 (4.5)

13 (10.2)

Stillbirth

33 (5.1)

24 (18.9)

Livebirth

459 (71.5)

55 (43.3)

Vaginal

96 (19.8)

25 (30.5)

Caesarean

387 (79.8)

57 (69.5)

Missing

2 (0.4)

0 (0.0)

2555 (1700–3250)

2100 (1415–2700)

Pregnancy outcomes
Early pregnancy loss <24 weeks

Mode of birth

Birth weight, g

Abbreviations: BMI body mass index, ICU intensive care unit, IQR interquartile range
*Obstetric reasons for admission included shock, massive postpartum hemorrhage, peripartum cardiomyopathy, amniotic fluid embolism, acute respiratory distress
secondary to antepartum hemorrhage, pulmonary edema secondary to pre-eclampsia, eclampsia, septic abortion, other septic complications, and surgical trauma.
**Non-obstetric reasons for admission included cardiac arrhythmia, pericardial effusions, cardiogenic pulmonary edema, pulmonary hypertension, cardiac arrest,
pneumonia, respiratory failure or arrest, gastrointestinal perforation/obstruction, diabetic keto-acidosis, deep venous thrombosis, thrombotic thrombocytopenic
purpura, posterior reversible encephalopathy syndrome, and severe infection with sepsis
‡ reasons are not mutually exclusive

outcome (3.8%, n = 16). Women in the highest-risk
group had a high incidence of adverse maternal outcome
(66.1%, n = 59). This is meaningfully greater than the

population prevalence of adverse outcome (16.5%), as is
reflected by the high LR associated with this category
(27.97, 95% confidence interval (CI) 16.91 to 46.27).
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Table 2 Incidence and definition of each of the components of the primary outcome
Definition

Total (n = 769),
n (%)

Total women with primary outcome

127 (16.5%)

Maternal death

Death during or within 42 days of delivery

59 (7.7%)

Maternal Morbidity

Occurrence of one or more of the defined organ support measures below

97 (12.6%)

Respiratory

Need for CPAP, BiPAP, or invasive ventilation

73

Cardiovascular

Need for use of inotropes or vasopressors

15

Renal

Renal replacement therapy for acute renal failure

14

Hepatic

Liver transplantation. Other management of hepatic failure include
ventilatory and circulatory support, management of elevated
intracranial pressure and renal failure, medical therapies for
hepatitis B virus (lamivudine); anticoagulation for Budd–Chiari syndrome.

21

Hematological

Massive transfusion of at least 5 units of blood products

60

Neurological

GCS score of less than 10

35

Uterine

Uncontrollable hemorrhage or infection leading to life-saving hysterectomy

16

Organ support

Abbreviations: BiPAP bilevel positive airway pressure, CPAP continuous positive airway pressure, GCS Glasgow Coma Scale
Maternal morbidities presented are not mutually exclusive and include those occurring in women who died. Morbidities have been grouped by organ system. All
organ system outcomes required use of life-saving treatment for more than 7 days to meet outcome criteria with the exception of hematological and
uterine support.

Internal validation

After 200 iterations of bootstrapping in each of the
10 imputed datasets, the pooled average optimism for
the AUROC was 0.013, which results in an
optimism-corrected AUROC for the CIPHER model
of 0.82 (95% CI 0.81 to 0.84). Minimal overestimation
of risk was identified after bootstrap analysis with a
resultant optimism-corrected calibration slope of 0.92
(95% CI 0.91 to 0.92) and intercept of −0.11 (95% CI
−0.13 to −0.08).
Subgroup analysis

All subgroup analyses demonstrated uniformity of
model fit with maintenance of discriminative

performance of the CIPHER model above our defined
threshold for adequate performance of AUROC of
more than 0.7. When the cohort was restricted to
only those cases admitted to the ICU during the
antenatal/intrapartum period, versus the post-partum
period, the AUROCs were estimated as 0.84 (95% CI
0.78 to 0.91) and 0.83 (95% CI 0.79 to 0.89), respectively. When the cohort was restricted to only those
cases admitted for obstetric causes versus those with
non-obstetric causes, the AUROCs were 0.85 (95% CI
0.80 to 0.90) and 0.82 (95% CI 0.76 to 0.88), respectively. When the cohort was restricted to either LMIC
facilities or HIC facilities, the AUROCs were estimated to be 0.851 (95% CI 0.812 to 0.894) versus

Table 3 Univariate and multivariable odds ratios for selected candidate predictor variables pooled from 10 imputed datasets
Patient characteristics multivariate analysis

Univariate OR (95% CI)

Multivariate OR (95% CI)

Maternal age, years

0.95 (0.92–0.98)

0.95 (0.92–0.99)

Surgery in preceding 24 h, yes

0.47 (0.32–0.70)

0.46 (0.29–0.73)

Highest systolic blood pressure, mm Hg

0.99 (0.98–1.02)

0.99 (0.98–1.00)

Lowest Glasgow Coma Scale score

0.85 (0.82–0.89)

0.87 (0.83–0.91)

Lowest ABG pH

0.60 (0.28–1.29)

0.57 (0.22–1.44)

Highest aPTT

1.02 (1.02–1.03)

1.02 (1.01–1.03)

Highest serum potassium

0.90 (0.72–1.12)

0.73 (0.56–0.94)

Highest serum sodium

1.07 (1.04–1.10)

1.03 (1.00–1.08)

Highest creatinine, per 10 unit change

1.05 (1.03–1.07)

1.04 (1.03–1.07)

Highest bilirubin, per 10 unit change

1.10 (1.07–1.14)

1.05 (1.01–1.09)

Abbreviations: ABG arterial blood gas, aPTT activated partial thromboplastin time, CI confidence interval, OR odds ratio
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Table 4 Final CIPHER (Collaborative Integrated Pregnancy Highdependency Estimate of Risk) model

Discussion

Logit(p) = 3.087 + [−1.912 × 10−5 (maternal age)3] + [−0.776(positive
surgical status within 24 h of admission)] + [−0.138 (Glasgow Coma
Scale score)] + [−7.123 × 10−3 (systolic blood pressure)] + [−0.319 (serum
potassium)] + [1.373 × 10−4 (serum sodium)2] + [4.934 × 10−3 (serum
bilirubin)] + [4.673 × 10−3 (serum creatinine)] + [1.584 × 10−2 (activated
partial thromboplastin time)] + [−0.570 (arterial blood gas pH)]
Maternal age (years); surgical status (yes/no); Glasgow Coma Scale score
(ordinal units); systolic blood pressure (millimeter of mercury); serum
bilirubin (micromole per liter); serum creatinine (micromole per liter)

We have developed and internally validated the CIPHER clinical risk prediction model to accurately assess risk of either death or the need for life-saving
prolonged organ support for pregnant or recently
pregnant women admitted to an ICU at 13 international sites. The final CIPHER model includes predictor variables that are readily available globally and
at relatively low cost. It is a simple model, including
only 10 predictors. After internal validation, CIPHER
affords high discrimination (0.82, 95% CI 0.81 to
0.84) and good calibration (slope of 0.92, 95% CI 0.91
to 0.92 and intercept of −0.11, 95% CI −0.13 to
−0.08). External validation of the model is now required prior to implementation of the model in clinical practice.

0.774 (95% CI 0.663 to 0.868), respectively. There was
a small but meaningful decrease in the point estimate
of AUROC when the analysis was restricted to only
HIC cases and the lower limit of the confidence
interval falls below the 0.7 threshold for a good
model.
When the CIPHER model was used to predict maternal death alone, the AUROC was 0.87 (95% CI 0.86 to
0.88). The discriminative performance of the APACHE 2
score for death during pregnancy or less than 6 weeks
post-partum in our ICU cohort was also high (AUROC
0.84, 95% CI 0.72 to 0.96). This analysis included only
433 women who had complete data on all 17 APACHE
2 predictor variables.

Main findings

Strengths and limitations

We have built on the previously successful work of this
collaborative team and developed the model on the basis
of clinical knowledge and a priori information about
relevant and globally available predictor variables. For
this study, we chose to use a composite outcome that reflects the important health burden of severe maternal
morbidities and goes beyond the traditional focus of

Fig. 2 Area under the receiver operating characteristic curve for the CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of
Risk) model plotted using the pooled predicted probabilities of outcome for each woman in the 10 imputed datasets. The area under the curve
of the receiver operating characteristic for this model prior to adjustment for overfitting is 0.84 (0.83–0.85)
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Fig. 3 Calibration plot of CIPHER (Collaborative Integrated Pregnancy High-dependency Estimate of Risk) model developed using the pooled
predicted probabilities of outcome for each woman in the 10 imputed datasets. The smooth line represents fit of the model predicted risk of
outcome to the observed rate within each decile of predicted probability. The straight diagonal line is used as reference for perfect fit. The bar
chart at the base of the figure presents distribution of cases with outcomes (above the line) and without cases (below the line) across the
spectrum of predicted probability

ICU risk scores on death alone. We believe that this
greatly expands the clinical utility of the CIPHER model.
Maternal mortality is thankfully on the decline. As mortality declines, severe maternal morbidity will become
even more relevant as an outcome to structure management strategies around. This model can now be easily
recalibrated for individual settings as long as the 10 predictor variables are available.
The CIPHER model was developed specifically for
use in obstetric ICU populations with a globally diverse cohort involving collaboration across 11 countries. Although inclusion of a diverse geographic
sample leads to an increase in global relevance, it also
likely contributed to a reduction in overall model performance at the local level. A reduction in overall
performance is evident when we compare performance seen in the high- and low- or middle-income
country subgroups. In both settings, performance is
maintained above the threshold for an adequate prognostic model (AUROC >0.7) but CIPHER is better at
discriminating between women with and without outcomes in the low- or middle-income population,
where the majority of outcomes occurred. A potential
weakness of the dataset used is the variability in outcome rates between sites; 88.6% of outcomes occurred
in LMIC sites, 57.6% solely in the Pakistan site. For
this reason, we recommend external validation and, if

required, recalibration of the model in each setting
individually before application in clinical care.
Performance of the CIPHER model to predict maternal death alone was similar to the APACHE II model in
our cohort. We chose to use both maternal death and
the need for life-saving organ support as a primary outcome in order to make the CIPHER model more clinically useful for a pregnant population than a model such
as APACHE II, which predicts death alone. Severe maternal morbidity is as significant in its life-altering consequences as mortality within this young and otherwise
healthy population of women.
Weaknesses of the study design included its retrospective nature, missing data due to incomplete data
entry, and unmeasured variables from some sites, precluding the potential for inclusion of those variables in
the final model. Over 100 cases were excluded because
of a high degree of missing data that we felt would have
undermined the benefit of the multiple imputation strategy to correct for missing data in the remaining cases.
This resulted in a smaller dataset than had been targeted
on the basis of our sample size calculation. We did not
achieve our a priori estimated sample size, but use of
multiple imputation in the remaining cases and the
higher rate of adverse outcomes than had been expected
resulted in an adequate sample size for model development. It is important to note that if we were to use the

82 (10.7)

59 (7.7)

769

25–49.9%

≥50%

Total

127

39 (66.1)

32 (39.0)

40 (18.9)

30.7 (23.0–39.6)

55.9 (46.8–64.6)

87.4 (80.0–92.4)

96.9 (95.1–98.0)

89.1 (86.4–91.3)

62.3 (58.4–66.0)

36.0 (32.2–39.8)

–

–
96.1 (90.6–98.5)

Specificity (95% CI)

Sensitivity (95% CI)

Sensitivity, specificity, and predictive values calculated using the upper limit of the risk range to define a positive test.
Abbreviations: CI confidence interval, LR likelihood ratio, NPV negative predictive value, PPV positive predictive value

212 (27.6)

10–24.9%

11 (8.7)

5 (2.1)

236 (30.7)

180 (23.4)

<5%

Observed outcome
in range, n (%)

Women in range, n (%)

5–9.9%

Predicted probability range

Table 5 Risk stratification table using five groups of predicted probability

66.1 (52.5–77.6)

50.4 (41.9–58.8)

31.4 (26.7–36.6)

22.9 (19.4–26.7)

–

PPV (95% CI)

87.6 (84.9–89.9)

91.1 (88.5–93.1)

96.2 (93.7–97.7)

97.9 (94.8–99.2)

–

NPV (95% CI)

27.97 (16.91–46.27)

9.18 (6.16–13.69)

3.34 (2.51–4.34)

0.93 (0.52–1.67)

0.31 (0.13–0.77)

LR (95% CI)
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same sample size formula with our observed outcome
rate of 16.5%, a sample size of 606 would be considered
adequate to generate robust estimates of model coefficients. We far exceeded that with our sample size of 769
women in the cohort used for analysis.
Another limitation is that because clinicians were
not masked to the results of the variables assessed in
the modeling, CIPHER is vulnerable to treatment
paradox [30]; this may be particularly true for the
protective nature of post-surgical status that may
modify both admission and intervention thresholds
and surveillance intensity.
Interpretation

Identifying the variables that predict outcome in pregnant
or recently pregnant women admitted to the ICU and developing a prediction model enables estimation of the likelihood of an adverse maternal event in the future on the
basis of information available at the time of a woman’s admission to the ICU. The candidate predictor variables for
the CIPHER model were those that were routinely and reliably measured, were readily available in hospitals worldwide, and had potential to inform or predict severity of
illness or outcome. The definition of severe maternal morbidity was organ- and management-based, reflecting the
true burden of disease in the ICU: both the need for organ
support and the impact of prolonged duration of organ
support and care.
In the development cohort, a threshold CIPHER
score of at least 50% was deemed a “positive” test for
the combined outcome to define a high-risk group.
The LR of 27.97 (95% CI 16.91 to 46.27) for this
group is strongly informative. In this group, with an
at least 50% CIPHER risk, there is evidence for action
as it identifies those women who are most at risk of
a combined outcome. In areas where resources are
available to manage additional case load or where
greater concern exists around impact of missing
true-positive cases, setting the threshold for high risk
as greater than 25% predicted probability remains informative with an LR of 9.18 (95% CI 6.16 to 13.69)
with only a small increase in associated false-positive
rate. This means that useful clinical information can
be gained from the CIPHER model in order to guide
care in a variety of contexts.
Four published studies have focused on development of
a maternal ICU outcome prediction model [10, 31–33].
Developed solely in Brazil, the Maternal Severity Index
used predefined, rather than statistically driven, WHO severity markers, identifying seven predictors of maternal
death, many of which were themselves composite predictors [10]. A secondary analysis of a cohort of maternal
general ICU admissions from the UK that focused on
evaluation of APACHE II variables identified medical
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history, heart rate, systolic blood pressure, and especially
Glasgow Coma Scale score as independently predictive of
maternal death [31]; however, they did not develop a multivariable prediction model. Nine independent variables
predictive of maternal death were identified in a West African (non-ICU) hospital-based study [32]. Of these, many
were indications for ICU admission in our study and were
not included as candidate predictor variables, including
severe anemia, malaria diagnosed during pregnancy, obstetric hemorrhage, pre-eclampsia or eclampsia, uterine
rupture, and genital infection or sepsis. Again, these variables were not formally combined to generate a comparable predictive model. A US military cohort was used to
develop a 13-variable risk assessment model to predict 38
maternal outcomes, including labor, delivery, maternal
morbidity, and death [33]. Performance of this model was
good with a reported AUROC of 0.75 for poor maternal
outcome, but the model is applicable only to the antenatal
period. None of these studies resulted in models overtly
applicable to critical care of obstetric patients in both
HICs and LMICs.
Future work in this area of research should focus on a
number of translational biomarkers poised to become
regular components of both maternity and critical care
and with potential to modify CIPHER [34, 35]. Prospective external and temporal validation studies of CIPHER
are required prior to its broad dissemination into communities of care, whether in LMICs or HICs. To support
work towards external validation we have provided a CIPHER calculator (see Additional file 2). An additional
goal for validation could be to expand the scope of the
CIPHER model to recalibrate in a population admitted
to a high-risk maternity unit in order to guide decisions
around admission to the ICU.

Conclusions
The CIPHER model determines the risk of death or need
for significant organ support in a population of pregnant
and post-partum women receiving critical care, with
clinical utility in both HICs and LMICs. CIPHER has the
potential to be a pragmatic risk prediction tool to identify women at highest risk for adverse ICU outcomes
and to assist with counseling patients and their families
regarding management within the ICU. Ultimately, once
validated, the CIPHER model could be applied globally
to reduce the burden of pregnancy-related morbidity
and mortality.
Additional files
Additional file 1: Table S1. CIPHER (Collaborative Integrated Pregnancy
High-dependency Estimate of Risk) cohort collaborators and site contribution.
Table S2. Patient characteristics and univariate analysis results generated
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through complete case analysis. Table S3. Characteristics of women with and
without missing data. (DOCX 43 kb)
Additional file 2: CIPHER (Collaborative Integrated Pregnancy Highdependency Estimate of Risk) model clinical calculator. (XLSX 12 kb)
Abbreviations
ABG: Arterial blood gas; APACHE: Acute Physiology And Chronic Health
Evaluation; aPTT: Activated partial thromboplastin time; AUROC: Area under
the curve of the receiver operating characteristic; CI: Confidence interval;
CIPHER: Collaborative Integrated Pregnancy High-dependency Estimate of
Risk; HIC: High-income country; ICU: Intensive care unit; LASSO: Least
Absolute Shrinkage and Selection Operator; LMIC: Low- and middle-income
countries; LR: Likelihood ratio; SOFA: Sepsis-related Organ Failure Assessment;
WHO: World Health Organization
Acknowledgments
CIPHER Group: Joni Kooy, Brittany Tarras, Nancy Liu, Rebecca Gordon,
Shannon Lockhart, Annie Tran, Run shan Felar Yu, Yisa Yen, Andy Dhaliwal,
Chris Lim, Nelson Luk, Saba Marzara and Navdeep Dha (Vancouver), Niamh
Barrett (Monash, Melbourne), Lucia Haritgan (National Maternity Hospital,
Dublin), Evan Lambe, Aoife Doyle, Aisling McMahon and Richard Katz
(Rotunda Hospital), Andrea Das Neves and Vanina Aphalo (Argentina), Marlot
Kallen (AMC, the Netherlands), Colleen Lee (Montefiore, New York), Katey
Austin, Mary Mahler, Dinusha Sen and Alina Blazer (Mount Sinai, Toronto),
Xiaotian Ni (Shanghai, China), Sheikh Irfan and Azra Amerjee (AKU, Pakistan),
Antonio F. Oliveira Neto, Mary Angela Parpinelli, Maria Laura Costa, Thais
Giovarotti, and Etienne Cordeiro (Campinas, Brazil).
Funding
This project was funded the Canadian Institutes for Health Research catalyst
grant: Maternal health: from Pre-conception to Empty Nest grant on 1/9/
2010 # H10–00654.
Most data were collected and shared without funding using internal resources.
Availability of data and materials
This project brought together datasets from 13 sites from around the world.
The data are available for other investigators use. Please contact PvD with
access requests.
Authors’ contributions
PvD, LAM, HR, KRW, BAP, and JAH were responsible for conceptualization of
the study. PvD, LAM, HR, KRW, BAP, SL, JL, ML, JAH, KJ, SaL, RQ, and ZAB
were responsible for planning the study, including design of the protocol,
data collection tools, and database. ZAB, MB, JGC, CC, TC, ACJMdP, OD, TD,
MK, JWG, MG, DG, StL, IL, EMH, FM, COH, BWM, PGRS, RT, TT, RQ, DV, EW, PY,
VZ, and KRW contributed data and carried out the study. BAP, HR, UVU, and
JB analyzed the data. BAP, HR, PvD, UVU, JB, LAM, and KRW drafted the
manuscript. All authors approved the final version of the manuscript.
Ethics approval and consent to participate
Independent research ethics board (REB) approval was obtained at each site,
and the CIPHER study was registered for REB approval in University of British
Columbia (UBC) (H10–00654).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1
Department of Obstetrics and Gynaecology, University of British Columbia,
2329 West Mall, Vancouver V6T 1Z4, BC, Canada. 2Department of
Anesthesiology, Pharmacology and Therapeutics, University of British
Columbia, 2329 West Mall, Vancouver V6T 1Z4, BC, Canada. 3BC Children’s

Page 12 of 13

Hospital Research Institute and Women’s Health Research Institute, University
of British Columbia, V3-336 950 W 28th Avenue, Vancouver, BC V5Z 4H4,
Canada. 4Department of Family Practice, University of British Columbia, 2329
West Mall, Vancouver V6T 1Z4, BC, Canada. 5Department of Medicine,
University of British Columbia, 2329 West Mall, Vancouver V6T 1Z4, BC,
Canada. 6School of Life Course Sciences, Faculty of Life Sciences and
Medicine, King’s College London, Strand, London WC2R2LS, UK. 7Center of
Excellence in Women & Child Health, Aga Khan University, Block 2 Clifton,
Karachi, Sindh, Pakistan. 8Centre for Global Child Health, the Hospital for Sick
Children, 555 University Ave, Toronto M5G 1X8, ON, Canada. 9Rotunda
Hospital, University College Dublin, 1, Parnell Square E, Dublin, Ireland.
10
Universidade Estadual de Campinas, Cidade Universitaria Zeferino Vaz Barao Geraldo, Campinas 13083-970, Sao Paulo, Brazil. 11Montefiore Medical
Center, Columbia University Medical Center, 951 Prospect Ave, Bronx 10459,
NY, USA. 12Morgan Stanley Children’s Hospital & Sloan Hospital for Mothers,
10032, 3959 Broadway, New York, NY, USA. 13Department of Obstetrics and
Gynaecology, Monash University, Wellington Rd, Clayton 3800, Victoria,
Australia. 14Academic Medical Centre, Meibergdreef 9, Amsterdam 1105, AZ,
The Netherlands. 15Inonu University, Bulgurlu Mahallesi, Malatya 44000,
Battalgazi, Turkey. 16Shanghai 1st Maternity and Infant Hospital, 200000, 536
Changle Rd, Shanghai, Jingan Qu, China. 17Mt Sinai Hospital, University of
Toronto, 600 University Ave, Toronto M5G1X5, ON, Canada. 18King Abdullah
University Hospital, Ar Ramtha 3030, Ramtha, Jordan. 19UCD Perinatal
Research Centre, School of Medicine, University College Dublin, National
Maternity Hospital, Belfield Downs, Dublin D14YH57, Ireland. 20Department of
Paediatrics and Women’s Health, University of Adelaide, Adelaide 5005, SA,
Australia. 21Hospital Interzonal General de Agudos Gral, Av. 101 Dr Ricardo
Balbin, Buenos Aires 3200, Argentina. 22Centre for Heart Lung Innovation, St
Paul’s Hospital, 1081 Burrard Street, Vancouver V6Z1Y6, BC, Canada.
Received: 12 April 2018 Accepted: 3 October 2018

References
1. Ryan HM, Sharma S, Magee LA, Ansermino JM, MacDonell K, Payne BA, et al.
The Usefulness of the APACHE II Score in Obstetric Critical Care: A
Structured Review. J Obstet Gynaecol Can. 2016;38:909–18.
2. Crozier TM, Wallace EM. Obstetric admissions to an integrated general
intensive care unit in a quaternary maternity facility. Aust N Z J Obstet
Gynaecol. 2011;51:233–8.
3. Lapinsky SE, Kruczynski K, Seaward GR, Farine D, Grossman RF. Critical care
management of the obstetric patient. Can J Anaesth. 1997;44:325–9.
4. Cook R, Cook D, Tilley J, Lee K, Marshall J. Multiple organ dysfunction:
baseline and serial component scores. Crit Care Med. 2001;29:2046–50.
5. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of
disease classification system. Crit Care Med. 1985;13:818–29.
6. Metnitz PG, Moreno RP, Almeida E, Jordan B, Bauer P, Campos RA, et al.
SAPS 3--From evaluation of the patient to evaluation of the intensive care
unit. Part 1: Objectives, methods and cohort description. Intensive Care
Med. 2005;31:1336–44.
7. Moreno RP, Metnitz PG, Almeida E, Jordan B, Bauer P, Campos RA, et al.
SAPS 3--From evaluation of the patient to evaluation of the intensive care
unit. Part 2: Development of a prognostic model for hospital mortality at
ICU admission. Intensive Care Med. 2005;31:1345–55.
8. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al.
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ
dysfunction/failure. On behalf of the Working Group on Sepsis-Related
Problems of the European Society of Intensive Care Medicine. Intensive
Care Med. 1996;22:707–10.
9. Oliveira-Neto A, Parpinelli MA, Cecatti JG, Souza JP, Sousa MH. Sequential
organ failure assessment score for evaluating organ failure and outcome of
severe maternal morbidity in obstetric intensive care. ScientificWorldJournal.
2012;2012:172145.
10. Souza JP, Cecatti JG, Haddad SM, Parpinelli MA, Costa ML, Katz L, et al. The
WHO maternal near-miss approach and the maternal severity index model
(MSI): tools for assessing the management of severe maternal morbidity.
PLoS One. 2012;7:e44129.
11. Ryan H, Jones M, Payne B, Sharma S, Hutfield AM, Lee T, et al. Validating the
performance of the Modified Early Obstetric Warning System multivariable
model to predict maternal intensive care admission. J Obstet Gynaecol Can.
2017;39:728–33.

Payne et al. Critical Care

(2018) 22:278

12. Lockitch G. Handbook of diagnostic biochemistry and haematology in
normal pregnancy. Boca Raton: CRC Press; 1993.
13. Philipp EE, Barnes J, Newton M. Scientific foundations of obstetrics and
gynaecology. 3rd ed. Oxford: Butterworth-Heinemann Ltd; 1987.
14. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study
of the number of events per variable in logistic regression analysis. J Clin
Epidemiol. 1996;49:1373–9.
15. Lapinsky SE, Hallett D, Collop N, Drover J, Lavercombe P, Leeman M, et al.
Evaluation of standard and modified severity of illness scores in the
obstetric patient. J Crit Care. 2011;26:535–7.
16. van Buuren S, Groothuis-Oudshoorn K. mice:Multivariate Imputation by
Chained Equations in R. J Stat Soft. 2016;45:1–67 url: http://www.jstatsoft.
org/v45/i03/.
17. Donders ART, van der Heijden GJMG, Stijnen T, Moons KGM. Review: A
gentle introduction to imputation of missing values. J Clin Epidemiol. 2006;
59:1087–91.
18. Moons KGM, Donders RART, Stijnen T, Harrell FE Jr. Using the outcome for
imputation of missing predictor values was preferred. J Clin Epidemiol.
2006;59:1092–101.
19. Tibshirani R. Regression shrinkage and selection via the Lasso. J R Stat Soc.
1996;58:267–88.
20. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized
Linear Models via Coordinate Descent. J Stat Softw. 2011;33:1–22 URL
http://www.jstatsoft.org/v33/i01/.
21. Rubin D. Multiple Imputation for Nonresponse in Surveys. New York: Wiley;
1987.
22. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver
operating characteristic (ROC) curve. Radiology. 1982;143:29–36.
23. De Cock B, Nieboer D, Van Calster B, Steyerberg E, Vergouwe Y (2016).
CalibrationCurves:Calibration performance. R package version 0.1.2.
24. Harrell FE Jr. (2018). rms: Regression Modeling Strategies. R package version
5.1–2. https://CRAN.R-project.org/package=rms.
25. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al.
Assessing the performance of prediction models: a framework for traditional
and novel measures. Epidemiology. 2010;21:128–38.
26. Deeks J, Altman D. Statistics notes - Diagnostic tests 4: likelihood ratios. Br
Med J. 2004;329:168–9.
27. Efron B, Tibshirani R. Improvements on Cross-Validation: The .632
Bootstrap Method. J Am Stat Assoc. 1997;(438):548–60. https://doi.org/
10.2307/2965703.
28. Payne BA, Hutcheon JA, Ansermino JM, Hall DR, Bhutta ZA, Bhutta SZ, et al.
A risk prediction model for the assessment and triage of women with
hypertensive disorders of pregnancy in low-resourced settings: the
miniPIERS (Pre-eclampsia Integrated Estimate of RiSk) multi-country
prospective cohort study. PLoS Med. 2014;11:e1001589.
29. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton PF, Cote AM, et al.
Prediction of adverse maternal outcomes in pre-eclampsia: development
and validation of the fullPIERS model. Lancet. 2011;377:219–27.
30. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in
developing models, evaluating assumptions and adequacy, and measuring
and reducing errors. Stat Med. 1996;15:361–87.
31. Harrison DA, Penny JA, Yentis SM, Fayek S, Brady AR. Case mix, outcome
and activity for obstetric admissions to adult, general critical care units: a
secondary analysis of the ICNARC Case Mix Programme Database. Crit Care.
2005;9(Suppl 3):S25–37.
32. Huchon C, Dumont A, Traore M, Abrahamowicz M, Fauconnier A, Fraser W,
et al. A prediction score for maternal mortality in Senegal and Mali. Obstet
Gynecol. 2013;121:1049–56.
33. Novicoff WM, Wagner DP, Knaus WA, Kane EK, Cecere F, Draper E, et al.
Initial development of a system-wide maternal-fetal outcomes assessment
program. Am J Obstet Gynecol. 2000;183:291–300.
34. Staff AC, Burke O, Benton S, von Dadelszen P, Szafranski P, Zhang C, et al.
Maternal circulating PlGF concentrations and placenta-related pregnancy
complications: First results from the CoLab AngF Study. Pregnancy
Hypertens. 2013;3:59.
35. Goldberg SA, Kharbanda B, Pepe PE. Year in review 2013: Critical Care--outof-hospital cardiac arrest, traumatic injury, and other emergency care
conditions. Crit Care. 2014;18:593.

Page 13 of 13

